12-Month Lobbying Summary - Organization

Hoffmann-La Roche Limited / Daniel Edgcumbe, President and C.E.O.

Registration Summary

Currently active - Last Updated: 2026-05-01

Who is lobbying?

Hoffmann-La Roche Limited (Address & business activities)

Daniel Edgcumbe, President and C.E.O.

Senior Officer in previous versions
- Brigitte Nolet, President and C.E.O.

Government Funding

Did Hoffmann-La Roche Limited receive government funding within the last 12 months? No

Other Entities (working together for the purposes of lobbying) Information

Hoffmann-La Roche Limited is not working together with any other entity for the purpose of lobbying.

Direct Interests of the Lobbying Activity

Affiliates

Hoffmann-La Roche Limited has the following affiliates that could have a direct interest in the outcome of the lobbying activities:

Hoffmann-La Roche Limited (Address information)
Roche Diagnostics (Address information)

Other Affiliates

The activities of Hoffmann-La Roche Limited are not controlled or directed by another person or organization with a direct interest in the outcome of this undertaking

Contributors with a Direct Interest in the Outcome

No person or organization contributed over $1000CDN, within the preceding 12 months, toward the lobbying activity on behalf of Hoffmann-La Roche Limited:

What is being lobbied?

Subject Matter of the Lobbying Activities

Details Regarding the Identified Subject Matter

Will any of the lobbyists listed within this registration arrange a meeting between a public office holder and any other individual for the purpose of attempting to influence any of the matters listed below:

Yes

Specific Topics of Lobbying Communications	Intended Outcomes	Associated Subject Matters
Advocacy regarding development of policies to address the public health threat of antimicrobial resistance and policies to encourage innovation in antimicrobial stewardship, surveillance and infection prevention and control.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health, Industry, Science and Technology
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Economic Development and Trade, Finances and Budgets, Health
Engage in discussions involving innovative diagnostics, government support and funding for screening and testing programs to benefit patients in BC, strengthening the diagnostic capability and capacity in the province, and identifying opportunities for partnership.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health, Hospitals, Science and Technology
Engage in discussions on artificial intelligence innovation and research in British Columbia, and explore opportunities for data sharing and utilizing real world evidence.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health, Hospitals, Science and Technology
Explore partnership and investment opportunities to support the growth of the life sciences sector in British Columbia.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health, Hospitals, Science and Technology
Further promote the contributions and positive impact of pharmaceutical innovation and the pharmaceutical industry in British Columbia and to increase awareness of the value of innovative therapies on the healthcare system.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health, Hospitals
Innovative medicines investment data sharing for clinical trials	Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Economic Development and Trade, Finances and Budgets, Health
Work with the Ministry of Health regarding public reimbursement of Roche’s innovative pharmaceutical products, and ensure any changes to pharmaceutical legislation support appropriate government reimbursement of innovative pharmaceuticals.	Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity	Health, Hospitals

Gifts or benefits provided by the organization

Gifts or Benefits Provided to Public Officer Holders
Name	Gift or Benefit Description	Circumstance	Date Promised	Value Promised	Date Given	Value Given
No Records

Who is being lobbied?

Ministries/Provincial Entities

Canadian Blood Services
Fraser Health Authority
Health
Innovate BC
Interior Health Authority
Jobs and Economic Growth
Member(s) of the BC Legislative Assembly
Northern Health Authority
Office of the Premier
Provincial Health Services Authority
University of British Columbia
Vancouver Coastal Health Authority
Vancouver Island Health Authority

Ministries/Provincial Entities in previous versions
- Jobs, Economic Development and Innovation

Who are the lobbyists?

In-house Lobbyists

Lobbyist

Contributions

Michele DElia
Subscribes to a Code of Conduct: Yes
Former Public Office Holder in BC: No